R&D Automation in Pharma and Chemistry: Outsourcing vs. In-House

Author: Alex Böser, Senior Innovation Lead Chemistry @ 5-HT Chemistry & Health

Introduction

Chemical and pharmaceutical R&D is increasingly complex and costly – e.g. developing a single new pharmaceutical drug can cost billions of dollars [1]. To stay competitive amid pressure for faster innovation, new products and lower costs, companies are turning to laboratory automation technologies at an unprecedented rate [2]. In fact, many leading companies (especially pharma) have been among the most progressive adopters of robotics and automation, using technology to boost productivity and contain rising R&D costs. Automation spans virtually all stages of R&D, from early discovery (e.g. high-throughput screenings) to preclinical testing, scale-up, and even manufacturing quality control. By reducing manual, labor-intensive tasks, these technologies improve experimental throughput, reproducibility, and data integrity. Automation – especially when augmented by AI for complex decision-making – is increasingly seen as a competitive differentiator that can shorten R&D cycles and increase success rates.

Against this backdrop, organizations face a pivotal choice in how to deploy automation: Outsource it or build it in-house. Outsourcing can take the form of utilizing “cloud labs” or advanced contract research organizations (CROs) that perform experiments on behalf of clients in automated facilities. This model promises immediate access to cutting-edge instrumentation and potential cost savings on infrastructure [3]. On the other hand, some companies invest in building in-house automated labs, integrating robotics, AI, and digital systems within their own R&D centers. This offers direct control over proprietary processes and potentially lower long-term costs if heavily utilized, but requires significant upfront investment and technical expertise.

Both approaches are gaining traction. Outsourcing of R&D is on the rise as companies seek greater flexibility and efficiency – many now contract out early-stage research and screening to external partners to remain competitive [5]. Simultaneously, major players are building state-of-the-art automated labs internally; for example, AstraZeneca’s advanced screening facility in the UK can test up to 300,000 compounds per day using robotics.

This article explores the trade-offs between outsourcing and in-house automation.

We will first overview modern R&D automation technologies and their applications. Then, we’ll compare the two approaches from technical and business perspectives, using real-world cases to illustrate pros and cons. Finally, we discuss emerging trends, risks, and strategic considerations to guide the reader in making the best decision for their situation.

(Note: All references to specific companies or products are for illustration from publicly available sources. No endorsement is implied.)

Automation Technologies Across R&D Stages

Today’s R&D automation encompasses a convergence of robotics, advanced instrumentation, and AI-driven software. Key technologies include:

Robotic Lab Systems: Automated liquid handlers, robotic arms, and integrated workcells can perform experiments with minimal human intervention. These systems excel at repetitive, high-volume tasks like compound screening, sample prep, or combinatorial synthesis. Modern setups operate 24/7 and coordinate multiple instruments in parallel, vastly exceeding human throughput. For instance, manual sample processing might achieve only a few dozen assays per day per scientist, whereas a well-designed robotic system can execute tens or even hundreds of thousands of assay measurements per day under optimal conditions. Robots also bring precision and consistency – they don’t tire or err due to lapses in attention, improving data quality and reproducibility.
AI-Driven Experimentation: Artificial intelligence and machine learning are increasingly integrated into lab automation. AI-driven synthesis planning tools (e.g. retrosynthesis software like Merck’s SYNTHIA) can rapidly propose routes to make target molecules, shortening what was once a laborious chemical planning process [5]. In combination with automated synthesizers and analyzers, AI algorithms can run closed-loop optimization – iteratively adjusting reaction conditions or molecular designs based on data.
High-Throughput Screening (HTS) and Analysis: High-throughput techniques allow researchers to test vast libraries of compounds or process variations quickly. Automation is critical here – companies employ HTS robotics to screen hundreds of thousands to millions of samples for activity across biological assays or chemical reactions. These systems integrate plate handling robots, detectors, and informatics to log results. The pharmaceutical industry has pioneered HTS in drug discovery for decades; now, improved automation and miniaturization have pushed HTS into areas like formulation optimization and bioprocess development. Process development labs also benefit from miniaturized, parallel experiments – for instance, automated bioreactor arrays can evaluate dozens of fermentation conditions simultaneously, greatly accelerating scale-up research [6].

Across early research, lead optimization, preclinical testing, and process scale-up, the goals of automation are consistent: increase experimental throughput and consistency, capture richer data, and ultimately shorten the R&D timeline. Implementing automation can shorten cycle times, improve reproducibility, and yield higher success rates in R&D. Additionally, robust automation in process development ensures smoother tech transfer from lab to manufacturing – data from automated experiments is more standardized and traceable, aiding regulatory compliance and scale-up reliability.

However, achieving these benefits requires significant infrastructure and expertise. This is where the question of outsourcing vs. in-house implementation becomes critical. Companies must decide whether to leverage external automated labs or invest in building their own. The following sections delve into this choice.

Outsourcing Automation: Cloud Labs and CROs

Outsourcing automated R&D involves handing off experimental work to a third-party that specializes in high-tech, automated laboratories. A notable model is the rise of “cloud labs”, which are essentially remote-controlled laboratories available as a service. As one definition puts it, a cloud lab is “a third-party laboratory that takes on experimental work on behalf of outsourcing organizations” [3]. These facilities are highly automated, equipped with broad arrays of instruments, and accessible via the internet. Scientists design experiments via a web interface or scripting API, and the cloud lab’s robotic systems execute the work, 24/7.

For example, Emerald Cloud Lab (ECL) – a pioneer in this space – houses 200+ types of scientific instruments in a centralized facility and allows researchers to remotely run experiments through a proprietary interface. The lab runs year-round, and clients can conduct a wide range of procedures (chemistry synthesis, analytical assays, bioassays, etc.) without ever setting foot in the lab [3]. The benefit is clear: companies gain access to state-of-the-art automation on demand, without needing to buy or maintain the equipment themselves - saving on real estate, construction, utilities, and equipment costs. Scientists focus on designing experiments and analyzing data, while the cloud provider handles physical execution and upkeep.

Beyond cloud labs, traditional Contract Research Organizations (CROs) are also adopting automation to offer faster and more scalable services. Many pharma companies already outsource research tasks to CROs (for chemistry, biology, toxicology, etc.) to tap external expertise or increase capacity [7]. Leading CROs and startups are now differentiating themselves by building fully automated platforms:

For instance, the startup Arctoris operates an automated drug discovery laboratory and partners with pharma/biotechs to perform biochemical assays, cell studies, and more with robotic precision [8]. (Notably, Arctoris in 2024 acquired a large automated R&D facility that Eli Lilly had originally built in-house – more on that case later.)
Similarly, Strateos offers cloud-based automation for drug discovery and even provides its software for implementation in clients’ own labs [3, 9].
Specialized providers like Culture Biosciences focus on automated bioreactors for early process development in biotech, running fermentation experiments as a service [10].

Advantages of Outsourcing

From a business perspective, outsourcing converts fixed costs into variable costs. Instead of spending capital on robots and instruments (which can run into the millions), companies pay per experiment or via subscription. This can be highly cost-effective, especially for smaller companies or those with intermittent R&D needs [12].

Outsourcing also dramatically reduces lead time: in some cases, it might take longer to purchase and set up the equipment in-house, than the cloud lab needs to deliver results. For fast-moving research programs, this speed to experimentation is a critical advantage.

Outsourcing can also provide scalability on demand. Need to screen an extra 100,000 compounds or run dozens of parallel syntheses this month? A large provider can often accommodate surges by leveraging their 24/7 automated workflows, without your organization having to procure anything new. If next month the demand drops, you simply dial down usage (and costs). This flexibility is particularly beneficial when R&D workloads are variable or when testing a new research direction without committing to infrastructure.

From a technical standpoint, outsourcing to an automation specialist offers cutting-edge capabilities that might be difficult to replicate internally. Providers like ECL or Strateos invest in maintaining comprehensive instrument inventories and advanced software. For example, ECL’s facility contains hundreds of instrument models covering chemistry, biology, and analytical techniques, far more than a typical single company lab could afford or manage. Additionally, outsourcing partners may offer compliance support (e.g. GxP compliant data and documentation for regulated work), which can be a boon for companies lacking that infrastructure.

Crucially, outsourcing does not necessarily mean ceding scientific control. Cloud labs in particular are designed to let the client’s scientists remain in the driver’s seat for experimental design. In contrast to a traditional CRO where you might send a protocol and wait for data, cloud lab users directly specify methods and parameters, almost as if the remote instruments were their own. The scientists build protocols in the cloud lab’s programmatic interface, and those protocols (written in the lab’s symbolic coding language) are owned by the client and can be reused and modified at will. This is a new paradigm of outsourcing where the line between internal and external blurs – researchers get the benefit of external infrastructure, yet operate it almost as an extension of their own lab.

Drawbacks of Outsourcing

Despite its attractions, outsourcing automation comes with trade-offs and risks. A primary concern is the loss of direct, hands-on control at the operational level. When using an external lab, you rely on the provider’s systems and staff to run things correctly. If something goes wrong in an experiment, troubleshooting can be slower and more opaque compared to an in-house lab – accumulating hidden costs.

There’s also a potential communication gap. Your scientists must precisely specify protocols and often engage in back-and-forth with the provider. Miscommunications or differences in interpretation can lead to experiments that don’t exactly match intent. Ensuring alignment requires diligent oversight.

Managing external projects itself can become an overhead. Coordinating with a cloud lab or CRO entails project management, scheduling, data transfer, and possibly training your staff to use the provider’s software. These activities consume time. Companies often underestimate how much effort goes into overseeing outsourced work. In some cases, firms have to dedicate or hire project managers specifically to handle CRO relationships when volumes grow. Scientists may need to stretch beyond their usual skill set to manage external partners, which can cause inefficiencies if not addressed [7].

There are also business and strategic risks. Outsourcing means your critical R&D knowledge and data are leaving the four walls of your organization. While reputable providers maintain confidentiality, some companies are uncomfortable relying on external labs for their most sensitive projects or IP-rich programs. Intellectual property generated in experiments belongs to the client in contractual terms, but the know-how – the practical insights from performing the work – may reside more with the provider’s systems than with your team. Over-reliance on outsourcing could lead to an erosion of internal expertise. If researchers become merely “requestors” of data and no longer cultivate hands-on skills, the company’s ability to innovate independently might suffer in the long run.

Another consideration is cost scalability: outsourcing is often cost-effective at small to medium scale, but if a company’s R&D grows to require constant, heavy use of automation, the cumulative service fees might rival or exceed the cost of owning equipment. Providers charge per experiment or per sample in many cases. Companies must analyze the crossover point at which building in-house could become cheaper for their volume of work.

Finally, outsourcing can create dependency and scheduling issues. You may be one of many clients, so queue times or availability could constrain your agility. If a critical experiment’s timing is at the mercy of an external queue or if the provider has an outage, it can impact project timelines. In contrast, an in-house facility under your direct control might be mobilized whenever needed (assuming you have capacity).

In summary, outsourcing R&D automation offers rapid access to advanced tech, lower upfront costs, and elastic capacity, at the expense of some control, potential hidden costs in coordination, and strategic dependence.

Next, we examine the flip side: building automation capabilities internally.

Building In-House Automation Facilities

Establishing an in-house automated R&D lab means investing in the robots, instruments, software, and personnel to run automated workflows within your own organization. Many large pharmaceutical and chemical companies have pursued this path, often under “lab of the future” initiatives. In-house automation can range from adding a few robotic workstations in an existing lab to constructing entire facilities designed around automation and digital integration (sometimes also called “smart labs” or “self-driving labs”).

Advantages of In-House Development

The foremost benefit is full control. The company owns the equipment and the process, enabling customization at every level. You can tailor the automation precisely to your specific research needs, which is ideal if you have unique assays or processes that external platforms can’t easily accommodate. Flexibility in this context is higher – if scientists want to modify a protocol on the fly or develop a novel technique, an internal automation team can implement those changes in the system. You are not limited to the menu of services or instruments a provider offers. This is particularly important for organizations pushing the cutting edge of science; for instance, if a novel analytical method or a custom piece of hardware is required, an in-house facility can integrate it, whereas an outsourced lab might not support it.

Owning the automation pipeline also means the data and IP stay entirely in-house. Sensitive information (compound structures, targets, etc.) doesn’t leave your secure network. For companies in competitive therapeutic areas, this assurance can outweigh cost considerations. Furthermore, by doing the work internally, your scientists and engineers accumulate deep expertise in the methods and technology. This knowledge can become a valuable intellectual asset. A well-developed internal automation capability can itself be a source of competitive advantage – enabling proprietary workflows that competitors cannot easily replicate. In a McKinsey study, labs that implemented automation broadly saw improvements in all key performance metrics and gained the ability to innovate faster than less-automated peers [2].

From a business standpoint, while the upfront investment is high, in-house automation can yield long-term cost efficiencies if utilized at scale. The capital expenditure buys you essentially unlimited use of the equipment (aside from maintenance costs). In high-throughput operations – for example, a screening group running millions of assays a year – owning the robots may be far cheaper over time than paying per assay fees to a provider. There is also the opportunity to design the facility for optimal workflow with other internal functions. For example, an automated medicinal chemistry lab can be located next to chemists and seamlessly integrated with in-house data systems, reducing friction in iteration cycles.

Large companies often justify automation investments with these scalability and integration benefits:

Eli Lilly in 2017 invested ~$90 million to build the “Life Sciences Studio,” a 11,500 sq. ft. fully automated lab integrating design, synthesis, purification, and testing in one platform [8]. This facility allowed Lilly’s scientists to remotely control experiments via cloud software, effectively a bespoke internal cloud lab. Such a resource gave Lilly end-to-end automation under one roof, enabling rapid iteration from molecule design to biological testing.
Similarly, Novartis has reported that its internal automation allowed processes that were once 30–40 samples per day by hand to scale up to hundreds of thousands of samples per day in throughput – an unimaginable increase without robotics [1].
AstraZeneca built automated modular laboratories in its Cambridge, UK site, capable of testing up to 300,000 compounds per day in screening assays [1].

These investments reflect a strategy to dramatically accelerate discovery internally and handle projects at a scale that outsourcing may not easily match (or would be extremely costly to outsource).

Another advantage of keeping automation in-house is alignment and speed for iterative research. When the robots are down the hall, scientists can get hands-on quickly if needed, adjust experiments in real time, and have direct visibility into the process. There is no need to package instructions for an external party or wait for scheduled slots – the feedback loop can be tighter. In process development scenarios, having in-house automated systems means your development engineers can continuously run and tweak experiments to refine a manufacturing process, with immediate cross-functional collaboration. This real-time aspect can shorten development cycles.

Drawbacks of In-House

The challenges of building in-house are significant. Cost is the most obvious barrier. Outfitting even a modest automation setup (robotic liquid handlers, storage systems, integrated analytical instruments, software licenses, facility renovations) can require millions in capital. Cutting-edge integrated labs like Lilly’s can run in the tens of millions of dollars. Beyond initial build, there are ongoing costs: maintenance contracts, calibration, software updates, and eventually equipment replacement as technology advances. Automation hardware can become obsolete or depreciate within a decade, so it’s a continuing investment to stay at the forefront.

There is also a skills and personnel requirement. Running an automated lab isn’t as simple as running a manual lab. Companies need automation engineers, software specialists, and data scientists in addition to domain scientists. Recruiting and retaining this talent can be difficult, especially for organizations whose core business is science, not engineering. The learning curve for scientists to effectively use complex robotic systems should not be underestimated – without sufficient training and a supportive culture, expensive automation might sit underutilized. A consulting study by Deloitte and others emphasized that adopting lab automation requires change management and upskilling staff, but when done right it can dramatically improve lab KPIs [2]. If done wrong, however, tools might be misused or experiments could be set up incorrectly, causing delays.

Another risk of going in-house is underutilization. If the automation facility is not used at high capacity, the return on investment is low. This can happen if R&D priorities shift or if the system’s capabilities don’t match the evolving needs of projects. A noteworthy scenario illustrating this risk is the fate of Lilly’s Life Sciences Studio: after some years of operation, Lilly decided to divest this automated platform. In 2024, the entire facility was acquired by Arctoris (a CRO) and moved to the UK to serve a broader set of clients. While details vary, it suggests that even a large pharma might find an internal automation asset underutilized or outside their new strategic focus, ultimately handing it off to an outsourcing specialist. This underscores that flexibility is not only a technical attribute but also a financial one – building fixed capacity in-house locks you in to a certain approach, whereas outsourcing is more fluid to turn on/off as needed.

Maintenance and downtime are additional considerations. When you run your own automated lab, any downtime directly halts your research. Companies must maintain spare parts and have engineers on call to fix robots or troubleshoot software. External providers distribute this risk across clients and have dedicated teams to ensure high uptime. In a small organization, a broken auto-sampler could pause work for days if no backup exists. In essence, by building in-house you assume the operational risk that providers otherwise absorb.

Finally, scaling an in-house facility for changing needs can be slow. If you suddenly need double the throughput, you have to procure more equipment or perhaps expand facilities – which could take months or years. In contrast, an outsourced model might allow relatively faster scaling by simply increasing your service level (assuming the provider has capacity). In-house setups can become bottlenecks if not planned with excess capacity.

To summarize, in-house automation empowers maximum control, customization, and potentially lower marginal costs at scale, but entails high upfront costs, the burden of maintenance, and the need for specialized talent and utilization to justify the investment.

Pros and Cons at a Glance – Technical and Business Perspectives

To crystallize the comparison, the tables below outline key pros and cons of outsourcing vs. in-house automation from both a technical and a business viewpoint.

Technical Considerations – Flexibility, IP, and Control:

Outsourcing (Technical Pros): Instant access to broad capabilities (hundreds of instrument types, latest technologies) that might not be available internally. Highly reproducible automated processes operated by experts, with 24/7 uptime ensuring more data faster. Compliance and data management frameworks provided (e.g. built-in LIMS, audit trails) without internal setup. Ability to run multiple complex workflows in parallel via cloud interfaces, something even well-staffed in-house labs may struggle to coordinate.
Outsourcing (Technical Cons): Limited customization if your needs fall outside the provider’s standard offerings (you are constrained by their menu of assays/instruments). Potential misalignment – the provider might execute protocols with subtle differences (their interpretation of your method), affecting results. Less real-time control: you cannot physically intervene if something unexpected happens mid-experiment. Data integration can require extra steps – ensuring external data feeds into your internal databases/ELN securely and in the right format can be an IT project on its own. Over time, scientists may lose some hands-on skills or process insight since they are not physically performing the experiments.
In-House (Technical Pros): Full control to design and tweak protocols on-demand. Systems can be custom-built or configured for specific processes unique to your pipeline. All data stays within internal systems – easier to integrate with proprietary databases and to apply internal analytics. Greater ability to innovate in methodology: you can try unconventional experiments without needing external approval or new contracts. IP is fully secured; any novel technique you develop on your equipment is your trade secret. Internal teams build know-how with each experiment, potentially leading to process improvements that become a competitive edge.
In-House (Technical Cons): Technology can become outdated – you might invest in a platform that is cutting-edge today but lags in 5–10 years, requiring further investment. Maintenance and reliability are on you; if a robot fails, your experiment halts until fixed (external labs often have redundancy). Ensuring robust data systems (LIMS, etc.) is your responsibility – some companies struggle to get the same level of digital integration that cloud labs offer out-of-the-box. Internal automation might also suffer from scope creep – trying to automate everything without sufficient expertise can lead to suboptimal implementations or frustrated scientists if the system is not user-friendly. Essentially, it demands a commitment to continuous improvement and support.

Business Considerations – Cost, Speed, and Scalability:

Outsourcing (Business Pros): Lower upfront cost and quicker startup: no need to build facilities, you can begin experiments within days or weeks by contracting a provider. Converts CapEx to OpEx – you pay for what you use, which is budget-friendly for many firms, especially startups or project-based work. Scalability and flexibility: ramp usage up or down as projects demand, without worrying about idle equipment or lab space. Access to expert support – providers often have method development and troubleshooting experts, meaning you effectively outsource some R&D labor costs as well. If a new technique or instrument is needed, the provider may add it faster than an internal purchasing process would allow (particularly if multiple clients will use it).
Outsourcing (Business Cons): Cumulative costs can become high at large scale or long durations – akin to “renting vs. buying,” long-term heavy use might favor buying. There may be contractual commitments, minimum fees, or premium pricing for priority access. Dependency risks: your R&D timeline is tied to the provider’s performance and stability; if they have downtime or business issues, you could be left scrambling. Some providers are startups themselves – one must assess their longevity and backup plans. Additionally, outsourcing can introduce organizational changes (e.g. roles of lab staff shift or some positions may become redundant), which can impact morale and company culture. There’s also less visibility into cost drivers – some costs (management time, delays) are hidden as noted in analyses of outsourcing, making it tricky to fully quantify ROI.
In-House (Business Pros): Long-term cost savings for high-volume operations – once the facility is up, the incremental cost of each experiment is relatively low (mostly reagents and utilities), and high throughput can bring economies of scale. You can also amortize the investment by using the lab for multiple programs and even multiple business units. There is potential for faster cycle times in iterative research since communication is internal and immediate; no waiting in a CRO queue. In-house capability can be a strategic asset – for example, enabling proprietary workflows that accelerate discovery could lead to more IP and faster drug candidates, which has huge business value. Some companies even treat their automation tech as part of their intellectual property portfolio (and in cases like Lilly’s, an asset that could be sold off if needed). Having in-house automation might also impress partners or investors by showcasing technological leadership.
In-House (Business Cons): High initial investment and fixed overhead: it can take months or years to build and validate an automated lab, which is a period of sunk cost before benefits accrue. If R&D priorities change (e.g. switching therapeutic focus), the facility might not fit new needs, leading to wasted capacity. Operating costs – skilled staff, service contracts, facility maintenance – are ongoing and must be budgeted regardless of short-term project lulls. In-house labs also face capacity limits; if suddenly tasked with a project beyond their throughput, they can become a bottleneck unless more capital is deployed. Additionally, return on investment may be hard to calculate; the benefits of faster research are real but can be diffuse (e.g. time saved in discovery doesn’t immediately show up on a balance sheet, yet it may increase the pipeline value). This can make it challenging to justify large expenditures to management without clear short-term ROI.

Real-World Case Studies and Examples

To ground the discussion, here are a few real-world examples illustrating how companies have approached the outsourcing vs. in-house automation decision:

Emerald Cloud Lab & Startup Use-Case: Pragma Bio, a small natural-products biotech, faced the classic build-or-buy dilemma for its analytical chemistry needs. They required expensive and diverse instruments (like LC–MS machines) to explore a wide range of molecules. Rather than spend huge capital on an in-house lab, Pragma Bio chose to utilize Emerald Cloud Lab’s remote facility. This gave them immediate access to top-tier instruments and automation without the multi-million dollar spend. Pragma’s scientists retained control by designing and coding their own experiments via ECL’s interface, effectively treating the cloud lab as an extension of their team. The outcome: they rapidly developed complex analytical methods (running over 700 automated LC–MS assays in one campaign) and iterated in a “software-like” cycle time, something that would have been impractical for them internally. Notably, they accomplished a quarter’s worth of experimental work before they could have even installed equipment had they gone the in-house route. This case highlights how cloud labs can empower startups to conduct sophisticated R&D early on, by outsourcing the physical aspect of experimentation but not the intellectual control [11].
Large Pharma In-House to Outsourced Transition: As mentioned earlier already, Eli Lilly’s Life Sciences Studio was an ambitious in-house automation project – a fully roboticized drug discovery platform built in 2017 with a $90M investment. It combined many R&D steps (compound design, synthesis, screening, etc.) in one facility, with remote operation capabilities. For years, Lilly used it internally to accelerate their research. However, by 2024 Lilly decided to divest this facility. It was acquired by Arctoris, a startup CRO specializing in automated discovery, and relocated to Arctoris’ site. By selling the lab, Lilly essentially shifted from an in-house model to an outsourcing model (at least for that kind of work) – Arctoris now provides automated discovery services to multiple clients using the ex-Lilly platform. The reasons weren’t publicly detailed, but one can speculate: Lilly may have refocused its R&D strategy, or found the utilization or maintenance of such a singular facility suboptimal in the long run. Arctoris, on the other hand, doubled its capacity overnight by obtaining this state-of-the-art lab, which it will leverage across many projects. This example underscores that the build vs. outsource decision is not static; a company can pivot. It also shows how a specialized automation provider (CRO) might run a large facility more efficiently by aggregating demand from many sponsors, whereas a single company might not fully utilize it.
Pharma Hybrid Approach & High-Throughput Screening: Many big pharma companies adopt a hybrid strategy. They build internal automation for core activities that are high volume and proprietary, while outsourcing other tasks. For example:
- Novartis has substantial in-house robotics for primary screening of chemical libraries (an essential, high-throughput task), but they might outsource specialty assays or certain chemistry tasks to CROs when internal resources are at capacity.
- Pfizer, Merck, GSK, and others have internal automated screening and compound management facilities – these are considered core competencies to keep in-house. On the other hand, they often outsource things like routine chemical synthesis or lead optimization trials to external partners when needed.

A general pattern is emerging: outsource early-stage or auxiliary tasks, keep the most critical or sensitive automation in-house. Indeed, one industry commentary suggests a pharma firm might “outsource the early stages of drug discovery and complete the remaining work in-house,” whereas a startup might do the reverse – everything in the cloud – because they have no lab of their own. This flexible division allows each organization to focus investment where it provides the most value.

These examples illustrate that there is no single “right” answer. Each organization finds a balance based on its unique context – resources, scale of research, expertise, and strategic priorities. In the next section, we will discuss the broader trends and factors to consider when making this decision.

Conclusion

Automation is becoming indispensable in chemistry and pharmaceutical R&D, offering unprecedented speed and efficiency from discovery through development. The fundamental question for R&D leaders is not whether to embrace automation, but how to deploy it. Outsourcing vs. in-house is a strategic decision with significant technical and business implications.

Outsourcing provides an attractive path for immediate access to advanced capabilities, minimal startup cost, and elastic scaling. It can empower even small organizations to perform cutting-edge research by leveraging external infrastructure. However, it introduces new challenges in coordination, potential loss of some control, and long-term cost considerations. It works best when used deliberately – for example, to handle overflow work, to execute well-defined standardized assays, or to jump-start projects without waiting for internal capacity.

Building in-house automation demands investment and foresight, but grants unparalleled control, security, and integration into your R&D engine. It can be a game-changer for organizations with sustained high R&D throughput or very specialized workflows. Companies like Novartis and AstraZeneca have demonstrated the huge productivity gains of internal automation, such as multiplying throughput by orders of magnitude and enabling experiments impossible by manual means. The payoff is maximized when the in-house system is fully utilized and aligned with the company’s core goals. The risks – high fixed costs, maintenance, and obsolescence – mean it’s a commitment that must be managed actively.

In many cases, the optimal solution is hybrid: retain internal capability for what you do best or must guard closely (your “secret sauce”), and outsource other aspects to trusted partners for efficiency. A thoughtful combination can yield the best of both worlds – agility, scale, and innovation. For example, some firms outsource early-stage screening to accelerate finding hits, then conduct lead optimization in their own automated lab to build IP-rich knowledge, and later outsource certain process development tasks to specialized CDMOs. This kind of nuanced approach requires continuously evaluating your portfolio and the external tools available.

When making the decision, consider the following strategic questions:

What is the scale and frequency of our experiments? (Small or sporadic needs favor outsourcing; large constant workloads may favor in-house.)
How unique or proprietary are our methods? (Unique methods might require custom in-house setups; standard ones can be outsourced safely.)
Do we have or can we build the expertise to run automation? (If not immediately, could a partnership help build that capability over time?)
What are the true costs and risks of each option over a 5-10 year horizon? (Include hidden costs like management overhead or potential opportunity cost of slower research.)
How important is speed to our competitive position? (Outsourcing can start faster; in-house can potentially iterate faster once established.)
Are there hybrid models that play to our strengths? (Identify which elements of R&D you must own versus which could be efficiently outsourced.)

By carefully weighing these factors and learning from industry examples, companies can devise a strategy that leverages automation to its fullest potential. Ultimately, whether outsourced, in-house, or a mix, the goal is the same: to accelerate innovation, improve R&D productivity, and deliver better products to market faster. Those who master the blend of technology and strategy in this decision will be well positioned in the new era of automated, data-driven R&D.

AI and Quality Assurance Disclaimer

This article has been structured, formatted, edited and written in parts with the help of 5-HT’s own AI agent, called “Hatty”. Every piece of text generated by Hatty has been revised, updated, enriched and cross-referenced by the author.

References

[1] HighRes Biosolutions. “Controlling Costs of Drug Discovery Through Automation.” (2022). Website: https://highresbio.com/news/controlling-costs-of-drug-discovery-through-automation

[2] Genentech News/GEN. “Laboratory Automation Reaches Every Stage of Drug Development.” (2023). Article: https://www.genengnews.com/topics/artificial-intelligence/laboratory-automation-reaches-every-stage-of-drug-development/

[3] Cichocki. Colabra Tech Blog. “Cloud labs: The future of scientific R&D.”(2023) Blog Article: https://www.colabra.ai/blog/cloud-labs-future-of-scientific-r-d/

[4] Buvailo. BiopharmaTrend (2023). Article: https://www.biopharmatrend.com/post/146-the-evolving-pharma-rd-outsourcing-industry-a-birds-eye-view/

[5] Buntz. Pharmaceutical Processing World. “Merck KGaA Q&A: Solving pharma’s ‘make’ step with SYNTHIA AI synthesis planning.” (2025). Article: https://www.pharmaceuticalprocessingworld.com/merck-kgaa-qa-solving-pharmas-make-step-with-synthias-ai-synthesis-planning/

[6] Broadley. Emerson Automation. “Automating Process Development Labs.” (2012). Article: https://www.emersonautomationexperts.com/2012/industry/life-sciences-medical/automating-process-development-labs/

[7] Blackburn. Emerald Cloud Lab. “Hidden Costs of Outsourcing.” (2021). Blog post: https://blog.emeraldcloudlab.com/hidden-costs-of-outsourcing/

[8] Kasianov. BioPharmTrend. “Eli Lilly Sells Automated Lab to Arctoris.” (2024). Article: https://www.biopharmatrend.com/post/949-eli-lilly-sells-automated-lab-to-arctoris-platform-relocates-to-oxford/

[9] Strateos Website: https://strateos.com/ (Accessed: 16.06.2025)

[10] Culture Biosciences Website: https://www.culturebiosciences.com/ (Accessed: 16.06.2025)

[11] Hostetler. Emerald Cloud Lab. “Cloud Case: Pragma Bio.” (2024). Blog post: https://blog.emeraldcloudlab.com/cloud-case-pragma-bio-x-emerald-cloud-lab/